Summary

The peritoneal dialysis market is projected to reach USD 14.16 billion by 2031 from USD 10.04 billion in 2026 at a CAGR of 6.0% during the forecast period.

Favorable healthcare policies in developed markets have greatly increased access to peritoneal dialysis, as many now offer reimbursement for home-based treatments. In most cases, the United States, Canada, and several other European countries have implemented policies that acknowledge the cost-effectiveness and greater benefits of peritoneal dialysis over in-center hemodialysis for patients. Such policies reduce barriers to treatment by providing reimbursement for a significant portion of PD-associated treatment costs. This could make PD a much more affordable and accessible form of therapy for patients, and reimbursement programs encourage healthcare providers to recommend PD for its flexibility and practicality, especially for those preferring home management of treatment. For instance, in the United States, Medicare's ESRD program encourages wider adoption by providing reimbursements for home dialysis. Likewise, other developed markets are also following and encouraging home dialysis since it reduces hospital admissions, improves patient outcomes, and reduces burdens on healthcare facilities. The financial support that comes with PD has become a reason for the aged and bedridden patients who have been able to live better as a result of reduced immobilization and enhanced personal care.

"The end-stage renal disease segment holds the largest market share in the global peritoneal dialysis market and is expected to grow at the highest CAGR during the forecast period."
Most healthcare systems promote home dialysis options to reduce hospital visits for end-stage renal disease (ESRD), thereby reducing overall healthcare costs. Health care providers would benefit from home peritoneal dialysis by reducing the need for in-center dialysis, thereby conserving hospital facility capacity and minimizing the problems it poses for both facilities and personnel. Home dialysis will also improve patients' lives by giving them control over their treatment. An added advantage of home-based PD is that it is very economical since it saves transportation costs, minimizes susceptibility to infection, and encourages continuity of care, which makes it an attractive modality for health care systems.

"The home care settings segment accounted for the largest market share in the global peritoneal dialysis market and is expected to grow at the highest CAGR during the forecast period."
Portable, user-friendly dialysis equipment has further improved the safety and ease of treatment for patients in the home setting. Modern peritoneal dialysis machines are well-designed, with intuitive interfaces, automation, and compact size, making them devices that patients can use with relative ease without relying heavily on medical knowledge. Thus, independent, comfortable home-based dialysis has reduced patients' dependence on healthcare professionals. Safety measures have improved with live monitoring and automatic alarms that enhance outcomes best dealt with early, before dangers occur. With those innovations, patients' confidence in managing their care improved, while treatment compliance generally increased.

"North America is expected to witness a substantial growth rate during the forecast period."
The peritoneal dialysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa by region. In 2023, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounted for the largest market share of the peritoneal dialysis market in 2025. North America is the largest regional market for peritoneal dialysis, partly because healthcare providers in the region have been trained to manage this treatment. This places them in a better position to ensure that patients requiring the treatment receive a holistic education on how to carry out procedures safely and effectively at home. Moreover, these professionals provide timely interventions through effective monitoring, thereby improving outcomes and reducing complications as much as possible. Specialized training programs and ongoing professional development in the region further underpin quality care. Such professionalism among healthcare professionals has indeed contributed to success in the introduction and spread of peritoneal dialysis in North America.

A breakdown of the primary participants (supply-side) for the peritoneal dialysis market referred to in this report is provided below:
・By Company Type: Tier 1:34%, Tier 2: 38%, and Tier 3: 28%
・By Designation: C-level: 26%, Director Level: 35%, and Others: 39%
・By Region: North America: 17%, Europe: 39%, Asia Pacific: 28%, Latin America: 8%, Middle East & Africa: 3%, GCC Countries: 5%
Prominent players in the peritoneal dialysis market are market Vantive (US), Fresenius Medical Care AG (Germany), Mozarc Medical (US), Davita Inc. (US), Becton, Dickinson and Company (US), Utah Medical Products, Inc. (US), Terumo Corporation (Japan), Diaverum AB (Sweden), Medionics (Canada), Newsol Technologies (Canada), Apollo Dialysis Pvt Ltd (India), U.S. Renal Care, Inc. (US), Northwest Kidney Centers (US), Relavo (US), Mitra Industries Pvt Ltd (India), JMS Co., Ltd. (Japan), among others.
Research Coverage
The report evaluates the peritoneal dialysis market and estimates the market size and future growth potential of this market based on various segments, including offerings, modality, disease indication, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will assist market leaders and new entrants with data on the nearest approximations of revenue numbers for the overall market, the peritoneal dialysis market, and the subsegments. The report will assist stakeholders in understanding the competitive landscape and gain further insights into better positioning their businesses and making appropriate go-to-market strategies. The report helps stakeholders understand the market pulse and provides data on key drivers, barriers, and opportunities in the market.
This report provides insights into the following points:
・ Analysis of key drivers Drivers (rising prevalence of chronic kidney diseases, growing prevalence of diabetes and hypertension, and technological advancements and increased investment in R&D) restraints (underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs)) opportunities (increasing growth opportunities in emerging economies, and surge in demand for home dialysis treatment), and challenges (growing incidence of treated kidney failure, and shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs)).
・Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global peritoneal dialysis market
・Market Development: Thorough knowledge and analysis of the profitable rising markets by offerings, modality, disease indication, end user, and region.
・Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global peritoneal dialysis market
・Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global peritoneal dialysis market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS AND EXCLUSIONS 26
1.3 STUDY SCOPE 27
1.3.1 SEGMENTS COVERED 27
1.4 YEARS CONSIDERED 28
1.5 CURRENCY USED 28
1.6 STAKEHOLDERS 29
1.7 LIMITATIONS 29
1.8 SUMMARY OF CHANGES 29
2 EXECUTIVE SUMMARY 30
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 30
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND START DEVELOPMENTS 32
2.3 DISRUPTIVE TRENDS SHAPING MARKET 33
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 34
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 35
3 PREMIUM INSIGHTS 36
3.1 PERITONEAL DIALYSIS MARKET OVERVIEW 36
3.2 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY PRODUCT AND COUNTRY 37
3.3 PERITONEAL DIALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 38
3.4 PERITONEAL DIALYSIS MARKET, BY REGION 39
3.5 PERITONEAL DIALYSIS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 39
4 MARKET OVERVIEW 40
4.1 INTRODUCTION 40
4.2 MARKET DYNAMICS 40
4.2.1 DRIVERS 41
4.2.1.1 Rising prevalence of chronic kidney diseases 41
4.2.1.2 Growing prevalence of diabetes and hypertension 42
4.2.1.3 Technological advancements and increased investment in R&D 43
4.2.2 RESTRAINTS 43
4.2.2.1 Underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs) 43
4.2.3 OPPORTUNITIES 44
4.2.3.1 Increasing growth opportunities in emerging economies 44
4.2.3.2 Surge in demand for home dialysis treatment 45
4.2.4 CHALLENGES 45
4.2.4.1 Shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs) 45
4.2.4.2 High risk of peritonitis as a barrier to peritoneal dialysis adoption 46
4.3 UNMET NEEDS AND WHITE SPACES 46
4.3.1 UNMET NEEDS IN PATIENT MONITORING DEVICES MARKET 47
4.3.2 WHITE SPACE OPPORTUNITIES 47
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 48
4.4.1 INTERCONNECTED MARKETS 48
4.4.2 CROSS-SECTOR OPPORTUNTIES 49
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 50
5 INDUSTRY TRENDS 51
5.1 PORTER’S FIVE FORCES ANALYSIS 51
5.1.1 THREAT OF NEW ENTRANTS 52
5.1.2 THREAT OF SUBSTITUTES 52
5.1.3 BARGAINING POWER OF SUPPLIERS 52
5.1.4 BARGAINING POWER OF BUYERS 52
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 52
5.2 MACROECONOMIC OUTLOOK 53
5.2.1 INTRODUCTION 53
5.2.2 GDP TRENDS AND FORECAST 53
5.2.3 TRENDS IN GLOBAL PERITONEAL DIALYSIS INDUSTRY 55
5.2.4 TRENDS IN GLOBAL HEALTHCARE & RENAL CARE INDUSTRY 55
5.3 SUPPLY CHAIN ANALYSIS 56
5.4 VALUE CHAIN ANALYSIS 57
5.5 ECOSYSTEM ANALYSIS 58
5.6 PRICING ANALYSIS 58
5.6.1 AVERAGE SELLING PRICE TREND, BY PRODUCT 58
5.6.2 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER 59
5.6.3 AVERAGE SELLING PRICE TREND OF PERITONEAL DIALYSIS MACHINES,
BY REGION 59
5.7 TRADE ANALYSIS 60
5.7.1 IMPORT SCENARIO (HS CODE 9018) 61
5.7.2 EXPORT DATA (HS CODE 9018) 61
5.8 KEY CONFERENCES & EVENTS, 2026–2027 62
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63
5.10 INVESTMENT AND FUNDING SCENARIO 63
5.11 CASE STUDY ANALYSIS 64
5.11.1 EXPANDING HOME-BASED PERITONEAL DIALYSIS THROUGH REMOTE PATIENT MONITORING 64
5.11.2 ENHANCING HOME PERITONEAL DIALYSIS MANAGEMENT WITH DIGITAL CONNECTIVITY 65
5.11.3 IMPROVING HOME DIALYSIS OUTCOMES THROUGH CONNECTED CARE 65
5.12 IMPACT OF 2025 US TARIFFS – PERITONEAL DIALYSIS MARKET 65
5.12.1 INTRODUCTION 65
5.12.2 KEY TARIFF RATES 66
5.12.3 PRICE IMPACT ANALYSIS 67
5.12.4 IMPACT ON COUNTRIES/REGIONS 68
5.12.4.1 North America 68
5.12.4.2 Europe 68
5.12.4.3 Asia Pacific 68
5.12.5 END-USE INDUSTRY IMPACT 69
5.13 PROCEDURE DATA ANALYSIS 69
5.13.1 PREVALENCE DATA FOR TREATED KIDNEY FAILURE 70
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT,
PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 74
6.1 KEY EMERGING TECHNOLOGIES 74
6.2 COMPLEMENTARY TECHNOLOGIES 74
6.2.1 REMOTE MONITORING SYSTEMS 75
6.3 TECHNOLOGY/PRODUCT ROADMAP 75
6.3.1 SHORT-TERM (2025–2027) | FOUNDATION & EARLY COMMERCIALIZATION 75
6.3.2 MID-TERM (2027–2030) | EXPANSION & STANDARDIZATION 76
6.3.3 LONG-TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION 76
6.4 PATENT ANALYSIS 77
6.4.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 78
6.5 FUTURE APPLICATIONS 78
6.5.1 AI-ENABLED REMOTE PERITONEAL DIALYSIS MANAGEMENT &
PREDICTIVE CARE 78
6.5.2 SMART PERITONEAL DIALYSIS ECOSYSTEMS 79
6.5.3 ADVANCED PERITONEAL DIALYSIS CONSUMABLES & BIOCOMPATIBLE SOLUTIONS 79
6.6 IMPACT OF AI/GEN AI ON PERITONEAL DIALYSIS MARKET 80
6.6.1 TOP USE CASES AND MARKET POTENTIAL 80
6.6.2 CASE STUDIES OF AI IMPLEMENTATION IN PERITONEAL DIALYSIS MARKET 80
6.6.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 81
6.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PERITONEAL DIALYSIS MARKET 82
7 REGULATORY LANDSCAPE 83
7.1 REGIONAL REGULATIONS AND COMPLIANCE 83
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
7.1.2 INDUSTRY STANDARDS 86
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 87
8.1 DECISION-MAKING PROCESS 87
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 87
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 87
8.2.2 KEY BUYING CRITERIA 88
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 89
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 90
8.5 MARKET PROFITABILITY 90
8.5.1 REVENUE POTENTIAL 91
8.5.2 COST DYNAMICS 91
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 91
9 PERITONEAL DIALYSIS MARKET, BY OFFERING 93
9.1 INTRODUCTION 94
9.2 PERITONEAL DIALYSIS PRODUCTS 94
9.2.1 PERITONEAL DIALYSIS SOLUTION BAGS 96
9.2.1.1 High demand for solutions to boost segmental growth 96
9.2.2 PERITONEAL DIALYSIS MACHINES 98
9.2.2.1 Rising prevalence of chronic diseases in emerging economies to boost adoption 98
9.2.3 PERITONEAL DIALYSIS CATHETERS 100
9.2.3.1 Favorable reimbursement policies to support market growth 100
9.2.4 PERITONEAL DIALYSIS TRANSFER SETS 101
9.2.4.1 Product recalls to limit market growth 101
9.2.5 OTHER PERITONEAL DIALYSIS PRODUCTS 102
9.3 PERITONEAL DIALYSIS SERVICES 103
9.3.1 BETTER PRIVACY AND INCREASED COMFORT OF AT-HOME DIALYSIS TREATMENT TO DRIVE MARKET 103
10 PERITONEAL DIALYSIS MARKET, BY MODALITY 105
10.1 INTRODUCTION 106
10.2 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) 106
10.2.1 SUPERIOR CLEARANCE OF HIGH-MOLECULAR-WEIGHT SUBSTANCES TO DRIVE MARKET 106
10.3 AUTOMATED PERITONEAL DIALYSIS (APD) 107
10.3.1 RISK OF RAPID DECLINE IN RESIDUAL RENAL FUNCTIONS TO LIMIT ADOPTION 107
11 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION 109
11.1 INTRODUCTION 110
11.2 END-STAGE RENAL DISEASE 110
11.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET 110
11.3 ACUTE KIDNEY INJURY 111
11.3.1 INCREASING HOSPITALIZATIONS TO PROPEL MARKET GROWTH 111
11.4 OTHER DISEASES 113
12 PERITONEAL DIALYSIS MARKET, BY END USER 114
12.1 INTRODUCTION 115
12.2 HOME CARE SETTINGS 115
12.2.1 LOWER COST AND SHORTER HOSPITAL STAYS TO AID MARKET GROWTH 115
12.3 HOSPITALS & INDEPENDENT DIALYSIS CENTERS 116
12.3.1 IMPROVED FACILITIES AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET 116
12.4 OTHER END USERS 119
13 PERITONEAL DIALYSIS MARKET, BY REGION 120
13.1 INTRODUCTION 121
13.1.1 PERITONEAL DIALYSIS PREVALENCE DATA 121
13.1.2 PERITONEAL DIALYSIS PROCEDURE DATA 122
13.2 NORTH AMERICA 124
13.2.1 US 127
13.2.1.1 US to account for largest market share during study period 127
13.2.2 CANADA 129
13.2.2.1 Shortage of dialysis facilities and increased treatment cost to limit market 129
13.3 EUROPE 131
13.3.1 GERMANY 134
13.3.1.1 Rising number of end-stage renal disease (ESRD) patients to boost market growth 134
13.3.2 UK 136
13.3.2.1 Increased number of new dialysis centers and technological advancements to support market growth 136
13.3.3 FRANCE 138
13.3.3.1 Low cost of peritoneal dialysis and consistent reimbursement policies to drive market growth 138
13.3.4 ITALY 140
13.3.4.1 Increasing research activities and growing patient population with acute renal failure to augment market growth 140
13.3.5 SPAIN 142
13.3.5.1 Favorable reimbursement scenario to boost market growth 142
13.3.6 REST OF EUROPE 145
13.4 ASIA PACIFIC 147
13.4.1 JAPAN 150
13.4.1.1 High prevalence of end-stage renal disease (ESRD) and large geriatric population to support market growth 150
13.4.2 CHINA 152
13.4.2.1 Increasing prevalence of diabetes and hypertension to drive market 152
13.4.3 INDIA 154
13.4.3.1 Favorable government initiatives and high prevalence of kidney disease to fuel market growth 154
13.4.4 AUSTRALIA 156
13.4.4.1 Increasing government initiatives about renal care to support market growth 156
13.4.5 SOUTH KOREA 159
13.4.5.1 Growing geriatric population with chronic kidney disease to propel market growth 159
13.4.6 REST OF ASIA PACIFIC 161
13.5 LATIN AMERICA 163
13.5.1 BRAZIL 165
13.5.1.1 Brazil to account for largest share of Latin American market during forecast period 165
13.5.2 MEXICO 167
13.5.2.1 Increasing patient population and growing middle class population to boost market growth 167
13.5.3 REST OF LATIN AMERICA 169
13.6 MIDDLE EAST & AFRICA 171
13.6.1 GROWING DEMAND FOR CONVENIENT AND ACCESSIBLE RENAL CARE TO PROPEL GROWTH 171
13.7 GCC COUNTRIES 174
13.7.1 HIGHER DISPOSABLE INCOME AND INCREASED GOVERNMENT HEALTHCARE EXPENDITURE TO PROPEL MARKET GROWTH 174
14 COMPETITIVE LANDSCAPE 177
14.1 OVERVIEW 177
14.2 KEY PLAYER STRATEGY/RIGHT TO WIN 177
14.3 REVENUE ANALYSIS 179
14.4 MARKET SHARE ANALYSIS 180
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 182
14.5.1 STARS 182
14.5.2 EMERGING LEADERS 182
14.5.3 PERVASIVE PLAYERS 183
14.5.4 PARTICIPANTS 183
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 184
14.5.5.1 Company footprint 184
14.5.5.2 Region footprint 185
14.5.5.3 Offering footprint 186
14.5.5.4 Modality footprint 187
14.5.5.5 Disease indication footprint 188
14.5.5.6 End-user footprint 189
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 189
14.6.1 PROGRESSIVE COMPANIES 189
14.6.2 RESPONSIVE COMPANIES 189
14.6.3 DYNAMIC COMPANIES 190
14.6.4 STARTING BLOCKS 190
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 191
14.6.5.1 Detailed list of key start-up/SME players 191
14.6.5.2 Competitive benchmarking of key startup/SME players 191
14.7 COMPANY VALUATION & FINANCIAL METRICS 192
14.8 BRAND/PRODUCT COMPARISON 193
14.9 COMPETITIVE SCENARIO 194
14.9.1 PRODUCT APPROVALS 194
14.9.2 DEALS 194
14.9.3 EXPANSIONS 195
14.9.3.1 Other developments 196
15 COMPANY PROFILES 197
15.1 KEY PLAYERS 197
15.1.1 FRESENIUS MEDICAL CARE AG 197
15.1.1.1 Business overview 197
15.1.1.2 Products & services offered 198
15.1.1.3 Recent developments 200
15.1.1.3.1 Deals 200
15.1.1.4 MnM view 200
15.1.1.4.1 Right to win 200
15.1.1.4.2 Strategic choices 200
15.1.1.4.3 Weaknesses & competitive threats 200
15.1.2 VANTIVE 201
15.1.2.1 Business overview 201
15.1.2.2 Products & services offered 202
15.1.2.3 Recent developments 203
15.1.2.3.1 Deals 203
15.1.2.4 MnM view 203
15.1.2.4.1 Right to win 203
15.1.2.4.2 Strategic choices 203
15.1.2.4.3 Weaknesses & competitive threats 204
15.1.3 DAVITA INC. 205
15.1.3.1 Business overview 205
15.1.3.2 Products & services offered 206
15.1.3.3 Recent developments 206
15.1.3.3.1 Deals 206
15.1.3.3.2 Expansions 206
15.1.3.4 Other developments 207
15.1.3.5 MnM view 207
15.1.3.5.1 Right to win 207
15.1.3.5.2 Strategic choices 207
15.1.3.5.3 Weaknesses & competitive threats 207
15.1.4 TERUMO CORPORATION 208
15.1.4.1 Business overview 208
15.1.4.2 Products & services offered 209
15.1.4.3 Recent developments 209
15.1.4.3.1 Product approvals 209
15.1.4.3.2 Deals 210
15.1.4.3.3 Expansions 210
15.1.4.4 MnM view 210
15.1.4.4.1 Right to win 210
15.1.4.4.2 Strategic choices 210
15.1.4.4.3 Weaknesses & competitive threats 211
15.1.5 BECTON, DICKINSON AND COMPANY 212
15.1.5.1 Business overview 212
15.1.5.2 Products & services offered 214
15.1.5.3 Recent developments 214
15.1.5.3.1 Expansions 214
15.1.5.4 MnM view 215
15.1.5.4.1 Right to win 215
15.1.5.4.2 Strategic choices 215
15.1.5.4.3 Weaknesses & competitive threats 215
15.1.6 UTAH MEDICAL PRODUCTS, INC. 216
15.1.6.1 Business overview 216
15.1.6.2 Products & services offered 218
15.1.7 MOZARC MEDICAL 219
15.1.7.1 Business overview 219
15.1.7.2 Products & services offered 220
15.1.8 DIAVERUM AB 221
15.1.8.1 Business overview 221
15.1.8.2 Products & services offered 221
15.1.9 MEDIONICS 222
15.1.9.1 Business overview 222
15.1.9.2 Products & services offered 222
15.1.10 NEWSOL TECHNOLOGIES INC. 224
15.1.10.1 Business overview 224
15.1.10.2 Products & services offered 224
15.1.11 APOLLO DIALYSIS PVT. LTD. 225
15.1.11.1 Business overview 225
15.1.11.2 Products & services offered 225
15.1.12 U.S. RENAL CARE, INC. 226
15.1.12.1 Business overview 226
15.1.12.2 Products & services offered 226
15.1.13 NORTHWEST KIDNEY CENTERS 227
15.1.13.1 Business overview 227
15.1.13.2 Products & services offered 227
15.1.13.3 Recent developments 228
15.1.13.3.1 Deals 228
15.1.13.3.2 Expansions 228
15.1.14 RELAVO 229
15.1.14.1 Business overview 229
15.1.14.2 Products & services offered 229
15.1.15 MITRA INDUSTRIES PVT. LTD. 230
15.1.15.1 Business overview 230
15.1.15.2 Products & services offered 230
15.2 OTHER PLAYERS 232
15.2.1 JMS CO., LTD. 232
15.2.2 AMECATH 232
15.2.3 POLYMEDICURE 233
15.2.4 HUAREN PHARMACEUTICAL 233
15.2.5 AWAK TECHNOLOGIES 234
15.2.6 INNOVATIVE RENAL CARE 234
15.2.7 ROMSONS 235
15.2.8 SSEM MTHEMBU MEDICAL (PTY) LTD. 235
15.2.9 RENAX BIOMEDICAL TECHNOLOGY CO., LTD. 236
15.2.10 ADVIN HEALTH CARE 236
16 RESEARCH METHODOLOGY 237
16.1 RESEARCH DATA 237
16.1.1 SECONDARY DATA 238
16.1.2 PRIMARY DATA 240
16.2 MARKET SIZE ESTIMATION 242
16.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 242
16.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 244
16.2.3 USAGE-BASED MARKET ESTIMATION 244
16.2.4 PRIMARY RESEARCH VALIDATION 247
16.3 GROWTH FORECAST ESTIMATION 247
16.4 DATA TRIANGULATION 249
16.5 STUDY ASSUMPTIONS 250
16.6 RISK ASSESSMENT 250
16.7 RESEARCH LIMITATIONS 250
17 APPENDIX 251
17.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 254
17.2 CUSTOMIZATION OPTIONS 256
17.3 RELATED REPORTS 256
17.4 AUTHOR DETAILS 257

ページTOPに戻る

List of Tables/Graphs

TABLE 1 INCLUSIONS AND EXCLUSIONS 26
TABLE 2 STANDARD USD CURRENCY CONVERSION RATES 28
TABLE 3 NUMBER OF PEOPLE AGED 65 YEARS OR OVER, BY REGION, 2022 VS. 2050 42
TABLE 4 UTILIZATION OF KIDNEY REPLACEMENT THERAPIES (PERITONEAL DIALYSIS VS. HEMODIALYSIS) 44
TABLE 5 COST OF KIDNEY REPLACEMENT THERAPIES 44
TABLE 6 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 50
TABLE 7 PERITONEAL DIALYSIS MARKET: PORTER’S FIVE FORCES 51
TABLE 8 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2021–2030 53
TABLE 9 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER, 2025 (USD) 59
TABLE 10 AVERAGE SELLING PRICE TREND OF PERITONEAL DIALYSIS MACHINES,
BY REGION, 2023–2025 (USD) 60
TABLE 11 IMPORT DATA FOR PERITONEAL DIALYSIS PRODUCTS UNDER HS CODE 9018,
BY COUNTRY, 2021–2025 (USD THOUSAND) 61
TABLE 12 EXPORT DATA FOR PERITONEAL DIALYSIS UNDER HS CODE 9018,
BY COUNTRY, 2021–2025 (USD THOUSAND) 62
TABLE 13 PERITONEAL DIALYSIS MARKET: DETAILED LIST OF KEY CONFERENCES
& EVENTS, 2026–2027 62
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 66
TABLE 15 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR PERITONEAL DIALYSIS 67
TABLE 16 PREVALENCE DATA, BY COUNTRY, 2021–2023 (PMP) 70
TABLE 17 NUMBER OF PERITONEAL DIALYSIS PATIENTS, BY REGION, 2019–2023 71
TABLE 18 NUMBER OF PERITONEAL DIALYSIS PATIENTS, BY REGION, 2024–2029 71
TABLE 19 PROCEDURE DATA FOR PERITONEAL DIALYSIS, BY COUNTRY, 2019–2023 72
TABLE 20 PROCEDURE DATA FOR PERITONEAL DIALYSIS, BY COUNTRY, 2024–2029 73
TABLE 21 TOP USE CASES AND MARKET POTENTIAL 80
TABLE 22 PERITONEAL DIALYSIS MARKET: CASE STUDIES RELATED TO AI IMPLEMENTATION 80
TABLE 23 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 81
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 29 GLOBAL STANDARDS IN PERITONEAL DIALYSIS MARKET 86
TABLE 30 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR PERITONEAL DIALYSIS PRODUCTS 88
TABLE 31 BUYING CRITERIA FOR PERITONEAL DIALYSIS PRODUCTS 89
TABLE 32 PERITONEAL DIALYSIS MARKET: UNMET NEEDS/END-USER EXPECTATIONS 90
TABLE 33 PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 94
TABLE 34 PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 95
TABLE 35 PERITONEAL DIALYSIS PRODUCTS MARKET, BY REGION/COUNTRY,
2024–2031 (USD MILLION) 95
TABLE 36 AVERAGE VOLUME OF EXCHANGE, BY REGION, 2021–2025 (MILLION LITERS) 96
TABLE 37 AVERAGE VOLUME OF EXCHANGE, BY REGION, 2027–2031 (MILLION LITERS) 97
TABLE 38 PERITONEAL DIALYSIS SOLUTION BAGS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 97
TABLE 39 PERITONEAL DIALYSIS SOLUTION BAGS MARKET, BY REGION,
2024–2031 (THOUSAND UNITS) 98
TABLE 40 PERITONEAL DIALYSIS MACHINES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 99
TABLE 41 PERITONEAL DIALYSIS MACHINES MARKET, BY REGION,
2024–2031 (THOUSAND UNITS) 100
TABLE 42 PERITONEAL DIALYSIS CATHETERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 101
TABLE 43 PERITONEAL DIALYSIS TRANSFER SETS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 102
TABLE 44 OTHER PERITONEAL DIALYSIS PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 103
TABLE 45 PERITONEAL DIALYSIS SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 104
TABLE 46 PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 106
TABLE 47 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 107
TABLE 48 AMBULATORY PERITONEAL DIALYSIS (APD) MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 108
TABLE 49 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 110
TABLE 50 PERITONEAL DIALYSIS MARKET FOR END-STAGE RENAL DISEASE,
BY REGION, 2024–2031 (USD MILLION) 111
TABLE 51 PERITONEAL DIALYSIS MARKET FOR ACUTE KIDNEY INJURY,
BY REGION, 2024–2031 (USD MILLION) 112
TABLE 52 PERITONEAL DIALYSIS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 113
TABLE 53 PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 115
TABLE 54 PERITONEAL DIALYSIS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 55 PERITONEAL DIALYSIS MARKET FOR HOSPITALS & INDEPENDENT DIALYSIS CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 56 PERITONEAL DIALYSIS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 57 PERITONEAL DIALYSIS PREVALENCE DATA, BY COUNTRY, 2021–2025 121
TABLE 58 PERITONEAL DIALYSIS PREVALENCE DATA, BY COUNTRY, 2026–2031 122
TABLE 59 PERITONEAL DIALYSIS PROCEDURE DATA, BY REGION,
2021–2025 (MILLION PROCEDURES) 122
TABLE 60 PERITONEAL DIALYSIS PROCEDURE DATA, BY REGION,
2025–2031 (MILLION PROCEDURES) 123
TABLE 61 PERITONEAL DIALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION) 123
TABLE 62 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 125
TABLE 63 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 125
TABLE 64 NORTH AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 125
TABLE 65 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 126
TABLE 66 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 126
TABLE 67 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 126
TABLE 68 US: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 127
TABLE 69 US: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 128
TABLE 70 US: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 128
TABLE 71 US: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 128
TABLE 72 US: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 129
TABLE 73 CANADA: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 130
TABLE 74 CANADA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 130
TABLE 75 CANADA: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 130
TABLE 76 CANADA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 131
TABLE 77 CANADA: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 131
TABLE 78 EUROPE: PERITONEAL DIALYSIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 132
TABLE 79 EUROPE: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 132
TABLE 80 EUROPE: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 132
TABLE 81 EUROPE: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 133
TABLE 82 EUROPE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 133
TABLE 83 EUROPE: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 133
TABLE 84 GERMANY: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 134
TABLE 85 GERMANY: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 135
TABLE 86 GERMANY: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 135
TABLE 87 GERMANY: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 135
TABLE 88 GERMANY: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 136
TABLE 89 UK: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 136
TABLE 90 UK: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 137
TABLE 91 UK: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 137
TABLE 92 UK: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 137
TABLE 93 UK: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 138
TABLE 94 FRANCE: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 139
TABLE 95 FRANCE: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 139
TABLE 96 FRANCE: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 139
TABLE 97 FRANCE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 140
TABLE 98 FRANCE: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 140
TABLE 99 ITALY: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 141
TABLE 100 ITALY: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 141
TABLE 101 ITALY: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 141
TABLE 102 ITALY: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 142
TABLE 103 ITALY: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 142
TABLE 104 SPAIN: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 143
TABLE 105 SPAIN: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 143
TABLE 106 SPAIN: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 143
TABLE 107 SPAIN: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 144
TABLE 108 SPAIN: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 144
TABLE 109 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 145
TABLE 110 REST OF EUROPE: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 145
TABLE 111 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 146
TABLE 112 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 146
TABLE 113 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 146
TABLE 114 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 115 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 148
TABLE 116 ASIA PACIFIC: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 148
TABLE 117 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 149
TABLE 118 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 149
TABLE 119 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 149
TABLE 120 JAPAN: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 150
TABLE 121 JAPAN: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 151
TABLE 122 JAPAN: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 151
TABLE 123 JAPAN: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 151
TABLE 124 JAPAN: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 152
TABLE 125 CHINA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 153
TABLE 126 CHINA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 153
TABLE 127 CHINA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 153
TABLE 128 CHINA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 154
TABLE 129 CHINA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 154
TABLE 130 INDIA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 155
TABLE 131 INDIA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 155
TABLE 132 INDIA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 155
TABLE 133 INDIA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 156
TABLE 134 INDIA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 156
TABLE 135 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 157
TABLE 136 AUSTRALIA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 157
TABLE 137 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 158
TABLE 138 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 158
TABLE 139 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 158
TABLE 140 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 159
TABLE 141 SOUTH KOREA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 159
TABLE 142 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 160
TABLE 143 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 160
TABLE 144 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 160
TABLE 145 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 161
TABLE 146 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 161
TABLE 147 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2024–2031 (USD MILLION) 162
TABLE 148 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 162
TABLE 149 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY END USER, 2024–2031 (USD MILLION) 162
TABLE 150 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 151 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 163
TABLE 152 LATIN AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 164
TABLE 153 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 164
TABLE 154 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 164
TABLE 155 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 165
TABLE 156 BRAZIL: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 165
TABLE 157 BRAZIL: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 166
TABLE 158 BRAZIL: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 166
TABLE 159 BRAZIL: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 166
TABLE 160 BRAZIL: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 167
TABLE 161 MEXICO: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 167
TABLE 162 MEXICO: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 168
TABLE 163 MEXICO: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2024–2031 (USD MILLION) 168
TABLE 164 MEXICO: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024–2031 (USD MILLION) 168
TABLE 165 MEXICO: PERITONEAL DIALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 169
TABLE 166 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2024–2031 (USD MILLION) 169
TABLE 167 REST OF LATIN AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 170
TABLE 168 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2024–2031 (USD MILLION) 170
TABLE 169 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 170
TABLE 170 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY END USER, 2024–2031 (USD MILLION) 171
TABLE 171 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2024–2031 (USD MILLION) 172
TABLE 172 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 172
TABLE 173 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2024–2031 (USD MILLION) 173
TABLE 174 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 173
TABLE 175 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET,
BY END USER, 2024–2031 (USD MILLION) 173
TABLE 176 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2024–2031 (USD MILLION) 174
TABLE 177 GCC COUNTRIES: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 175
TABLE 178 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2024–2031 (USD MILLION) 175
TABLE 179 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2024–2031 (USD MILLION) 176
TABLE 180 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET,
BY END USER, 2024–2031 (USD MILLION) 176
TABLE 181 KEY DEVELOPMENTS IN PERITONEAL DIALYSIS MARKET,
JANUARY 2021–JULY 2026 177
TABLE 182 PERITONEAL DIALYSIS MARKET: DEGREE OF COMPETITION 181
TABLE 183 PERITONEAL DIALYSIS MARKET: REGION FOOTPRINT, 2025 185
TABLE 184 PERITONEAL DIALYSIS MARKET: OFFERING FOOTPRINT, 2025 186
TABLE 185 PERITONEAL DIALYSIS MARKET: MODALITY FOOTPRINT, 2025 187
TABLE 186 PERITONEAL DIALYSIS MARKET: DISEASE INDICATION FOOTPRINT, 2025 188
TABLE 187 PERITONEAL DIALYSIS MARKET: END-USER FOOTPRINT, 2025 189
TABLE 188 PERITONEAL DIALYSIS MARKET: DETAILED LIST OF KEY
START-UP/SME PLAYERS, 2025 191
TABLE 189 PERITONEAL DIALYSIS MARKET: COMPETITIVE BENCHMARKING
OF KEY STARTUP/ SME PLAYERS, 2025 191
TABLE 190 PERITONEAL DIALYSIS MARKET: PRODUCT APPROVALS,
JANUARY 2021–JULY 2026 194
TABLE 191 PERITONEAL DIALYSIS MARKET: DEALS, JANUARY 2021–JULY 2026 194
TABLE 192 PERITONEAL DIALYSIS MARKET: EXPANSIONS, JANUARY 2021–JULY 2026 195
TABLE 193 PERITONEAL DIALYSIS MARKET: OTHER DEVELOPMENTS,
JANUARY 2021–JULY 2026 196
TABLE 194 FRESENIUS MEDICAL CARE AG: COMPANY OVERVIEW 197
TABLE 195 FRESENIUS MEDICAL CARE AG: PRODUCTS & SERVICES OFFERED 198
TABLE 196 FRESENIUS MEDICAL CARE AG: DEALS 200
TABLE 197 VANTIVE: COMPANY OVERVIEW 201
TABLE 198 VANTIVE: PRODUCTS & SERVICES OFFERED 202
TABLE 199 VANTIVE: DEALS 203
TABLE 200 DAVITA INC.: COMPANY OVERVIEW 205
TABLE 201 DAVITA INC.: PRODUCTS & SERVICES OFFERED 206
TABLE 202 DAVITA INC.: DEALS 206
TABLE 203 DAVITA INC.: EXPANSIONS 206
TABLE 204 DAVITA INC.: OTHER DEVELOPMENTS 207
TABLE 205 TERUMO CORPORATION: COMPANY OVERVIEW 208
TABLE 206 TERUMO CORPORATION: PRODUCTS & SERVICES OFFERED 209
TABLE 207 TERUMO CORPORATION: PRODUCT APPROVALS 209
TABLE 208 TERUMO CORPORATION: DEALS 210
TABLE 209 TERUMO CORPORATION: EXPANSIONS 210
TABLE 210 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 212
TABLE 211 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED 214
TABLE 212 BECTON, DICKINSON AND COMPANY: EXPANSIONS 214
TABLE 213 UTAH MEDICAL PRODUCTS, INC.: COMPANY OVERVIEW 216
TABLE 214 UTAH MEDICAL PRODUCTS, INC.: PRODUCTS & SERVICES OFFERED 218
TABLE 215 MOZARC MEDICAL: COMPANY OVERVIEW 219
TABLE 216 MOZARC MEDICAL: PRODUCTS & SERVICES OFFERED 220
TABLE 217 DIAVERUM AB: COMPANY OVERVIEW 221
TABLE 218 DIAVERUM AB: PRODUCTS & SERVICES OFFERED 221
TABLE 219 MEDIONICS: COMPANY OVERVIEW 222
TABLE 220 MEDIONICS: PRODUCTS & SERVICES OFFERED 222
TABLE 221 NEWSOL TECHNOLOGIES INC.: COMPANY OVERVIEW 224
TABLE 222 NEWSOL TECHNOLOGIES INC.: PRODUCTS & SERVICES OFFERED 224
TABLE 223 APOLLO DIALYSIS PVT. LTD.: COMPANY OVERVIEW 225
TABLE 224 APOLLO DIALYSIS PVT. LTD.: PRODUCTS & SERVICES OFFERED 225
TABLE 225 U.S. RENAL CARE, INC.: COMPANY OVERVIEW 226
TABLE 226 U.S. RENAL CARE, INC.: PRODUCTS & SERVICES OFFERED 226
TABLE 227 NORTHWEST KIDNEY CENTERS: COMPANY OVERVIEW 227
TABLE 228 NORTHWEST KIDNEY CENTERS: PRODUCTS & SERVICES OFFERED 227
TABLE 229 NORTHWEST KIDNEY CENTERS: DEALS 228
TABLE 230 NORTHWEST KIDNEY CENTERS: EXPANSIONS 228
TABLE 231 RELAVO: COMPANY OVERVIEW 229
TABLE 232 RELAVO: PRODUCTS & SERVICES OFFERED 229
TABLE 233 MITRA INDUSTRIES PVT. LTD.: COMPANY OVERVIEW 230
TABLE 234 MITRA INDUSTRIES PVT. LTD.: PRODUCTS & SERVICES OFFERED 230
TABLE 235 STUDY ASSUMPTIONS 250
TABLE 236 RISK ASSESSMENT 250

FIGURE 1 PERITONEAL DIALYSIS MARKET SEGMENTATION 27
FIGURE 2 STUDY YEARS CONSIDERED 28
FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS 30
FIGURE 4 PERITONEAL DIALYSIS MARKET, 2024–2031 (USD MILLION) 31
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PERITONEAL DIALYSIS MARKET 32
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF PERITONEAL DIALYSIS MARKET 33
FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN PERITONEAL
DIALYSIS MARKET, 2026 34
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 35
FIGURE 9 STRINGENT REGULATORY FRAMEWORK TO DRIVE MARKET GROWTH 36
FIGURE 10 HOMECARE SEGMENT TO ACCOUNT FOR LARGEST SHARE OF
NORTH AMERICAN MARKET IN 2025 37
FIGURE 11 INDIA TO REGISTER HIGHEST GROWTH RATE FROM 2026 TO 2031 38
FIGURE 12 NORTH AMERICA TO ACCOUNT FOR LARGEST MARKET SHARE TILL 2031 39
FIGURE 13 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE 39
FIGURE 14 PERITONEAL DIALYSIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 40
FIGURE 15 CANADA: NUMBER OF END-STAGE RENAL DISEASE PATIENTS,
BY AGE GROUP (2025) 41
FIGURE 16 US: REPORTED CAUSES OF END-STAGE RENAL DISEASE (2025) 42
FIGURE 17 SHORTAGES OF NEPHROLOGISTS IN LOW-INCOME AND LOWER-MIDDLE-INCOME COUNTRIES (LLMICS) 46
FIGURE 18 PERITONEAL DIALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 51
FIGURE 19 PERITONEAL DIALYSIS MARKET: SUPPLY CHAIN ANALYSIS 57
FIGURE 20 PERITONEAL DIALYSIS MARKET: VALUE CHAIN ANALYSIS 57
FIGURE 21 PERITONEAL DIALYSIS MARKET: ECOSYSTEM ANALYSIS 58
FIGURE 22 AVERAGE SELLING PRICE TREND OF PERITONEAL DIALYSIS MACHINES,
BY REGION, 2023–2025 (USD) 60
FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63
FIGURE 24 PERITONEAL DIALYSIS MARKET: INVESTMENT & FUNDING SCENARIO, 2019–2023 64
FIGURE 25 NUMBER OF PATENTS PUBLISHED, JANUARY 2016─JULY 2026 77
FIGURE 26 TOP APPLICANT COUNTRIES/REGIONS FOR PERITONEAL
DIALYSIS (JANUARY 2016− JULY 2026) 78
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PERITONEAL
DIALYSIS PRODUCTS 88
FIGURE 28 KEY BUYING CRITERIA FOR PERITONEAL DIALYSIS PRODUCTS 88
FIGURE 29 NORTH AMERICA: PERITONEAL DIALYSIS MARKET SNAPSHOT 124
FIGURE 30 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET SNAPSHOT 147
FIGURE 31 REVENUE ANALYSIS OF TOP PLAYERS IN PERITONEAL DIALYSIS MARKET,
2023–2025 (USD MILLION) 179
FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 180
FIGURE 33 PERITONEAL DIALYSIS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 183
FIGURE 34 PERITONEAL DIALYSIS MARKET: COMPANY FOOTPRINT, 2025 184
FIGURE 35 PERITONEAL DIALYSIS MARKET: COMPANY EVALUATION MATRIX
(START-UPS/SMES), 2025 190
FIGURE 36 EV/EBITDA OF KEY VENDORS, 2026 192
FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS, 2026 192
FIGURE 38 BRAND/PRODUCT COMPARATIVE ANALYSIS 193
FIGURE 39 FRESENIUS MEDICAL CARE AG: COMPANY SNAPSHOT 198
FIGURE 40 DAVITA INC.: COMPANY SNAPSHOT 205
FIGURE 41 TERUMO CORPORATION: COMPANY SNAPSHOT 208
FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 213
FIGURE 43 UTAH MEDICAL PRODUCTS, INC.: COMPANY SNAPSHOT 217
FIGURE 44 RESEARCH DESIGN: PERITONEAL DIALYSIS MARKET 237
FIGURE 45 INDICATIVE LIST OF SECONDARY SOURCES 239
FIGURE 46 LIST OF KEY PRIMARY SOURCES 240
FIGURE 47 KEY INDUSTRY INSIGHTS 241
FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 241
FIGURE 49 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE,
DESIGNATION, AND REGION 242
FIGURE 50 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 243
FIGURE 51 REVENUE SHARE ANALYSIS ILLUSTRATION 243
FIGURE 52 SUPPLY-SIDE MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS MARKET (2025) 244
FIGURE 53 ESTIMATION OF PERITONEAL DIALYSIS PROCEDURES, BY COUNTRY/REGION 245
FIGURE 54 MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS MARKET,
BY PRODUCT UTILIZATION METHODOLOGY 245
FIGURE 55 MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS SERVICES MARKET,
BY REVENUE MAPPING METHODOLOGY 246
FIGURE 56 PERITONEAL DIALYSIS: AVERAGE VOLUME EXCHANGE ESTIMATION MODEL 246
FIGURE 57 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031) 248
FIGURE 58 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 248
FIGURE 59 DATA TRIANGULATION METHODOLOGY 249